U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER HORIUCHI 4 TRANMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PRIORITY CL 11 May 2000 PCT/JP00/03017 14 May 1999 TITLE OF INVENTION HAIR GROWTH STIMILANTS APPLICANT(S) FOR DO/EO/US Isan HORTICHT TUESADY - (MONDAY WAS A HOLIDAY) CN Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. [X] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. [] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. [] The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31). 5 [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. [] is attached hereto (required only if not transmitted by the International Bureau). b. [X] has been communicated by the International Bureau. ui c. | is not required, as the application was filed in the United States Receiving Office (RO/US). 6. [X] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. [] are transmitted herewith (required only if not transmitted by the International Bureau). b. [] have been communicated by the International Bureau. O c. [] have not been made; however, the time limit for making such amendments has NOT expired. d. [X] have not been made and will not be made. 8. [] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). [1,9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

[2,0. [] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 1 Items 11. to 16. below concern document(s) or information included: 11. [X] An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. [] A FIRST preliminary amendment. [] A SECOND or SUBSEQUENT preliminary amendment. 14. [] A substitute specification. 15. [] A change of power of attorney and/or address letter. 16. [X] Other items or information: [X] Courtesy copy of the first page of the International Publication (WO 00/69399).

[X] Formal drawings, 1 sheets, Figures 1-1.

[X] Courtesy Copy of the International Search Report.

[X] Applicant claims small entity status. See 37 CFR 1.27.

Page 1 of 2

٠

U.S. APPLICATION NO. (If known, see 37 CFR	1.5) International	al Application No.		Attorney's Docket	Vo.
09/743	704	JP00/03017		HORIUCHI	
17. [xx] The following fees are submitted:				CALCULATIONS	PTO LISE ONLY
BASIC NATIONAL FEE (37 CFR	1.492 (a)(1) -(5):			CILCULATION	7 TO USE UNLT
Neither international preliminary exa	amination fee (37 C	FR 1.482)			
nor international search fee (37 CFR	1.445(a)(2)) paid t	o USPTO			
and International Search Report not 1	prepared by the EPC	J or JPO	.\$1000.00		
International preliminary examination USPTO but International Search Re	on fee (37 CFR 1.48 port prepared by the	32) not paid to e EPO or JPO	\$860.00		
Internal of the control of					
International preliminary examination international search fee (37 CFR 1.4	on fee (37 CFR 1.48 145(a)(2)) paid to U	32) not paid to USPTC SPTO	but \$710.00		
International preliminary examination but all claims did not satisfy provision	on fee paid to USPT	O (37 CFR 1.482)	\$690.00		
International preliminary examination	on fee paid to USPT	O (37 CFR 1 482)			
and all claims satisfied provisions of	PCT Article 33(1)	-(4)	\$100.00		
ENTER APP	ROPRIATE B.	ASIC FEE AMO	UNT =	\$ 860.00	
Surcharge of \$130.00 for furnishing th	e oath or declaratio	n later than [120 [130	\$	
months from the earliest claimed prior	ity date (37 CFR 1.	.492(e)).			
Claims as Originally Presented	Number Filed		Rate		
-Total Claims	6 - 20		X \$18.00	\$	
Independent Claims	l - 3		\$80.00	\$	
Multiple Dependent Claims (if applica			+\$270.00	\$	
TO	TAL OF ABOV	E CALCULATI	ONS =	\$ 860.00	
Claims After Post Filing Prel. Amend	Number Filed	Number Extra I	Rate		
Total Claims	- 20	2	X \$18.00	\$	
Independent Claims	- 3	2	X \$78.00	\$	
TO:	TAL OF ABOV	E CALCULATION	ONS =	\$ 860.00	
Reduction of ½ for filing by small enti- status. See 37 CFR 1.27.	ty, if applicable. A	pplicant claims small	entity	\$ 430.00	
1		SUBTO	TAL =	\$ 430.00	
Processing fee of \$130.00 for furnishing months from the earliest claimed prior	g the English transl ity date (37 CFR 1.	lation later than [] 2 492(f)).	0 [] 30	S	
	TOT	AL NATIONAL	FEE =	\$ 430.00	
Fee for recording the enclosed assignment	ent (37 CFR 1.21(1	h)). The assignment n	nust be	S	
accompanied by an appropriate cover s	heet (37 CFR 3.28,	, 3.31). \$40.00 per pro	perty +		
	TOT	AL FEES ENCL	OSED =	\$ 430.00	
				Amount to be:	\$
				refunded	
a. [] A check in the amount of \$				charged	\$
b. [X] Credit Card Payment Form (P)	to cov	ver the above fees is e	nclosed.		
c. [] Please charge my Deposit Acc	ount No. 02-4035 i	ng payment in the amo	ount of \$ 43	0.00, is attached.	
d. [XX] The Commissioner is hereby to Deposit Account No. 02-40	authorized to charg 35. A. duplicate co	ge any additional fees py of this sheet is encl	which may l losed.	oe required, or credit as	y overpayment
NOTE: Where an appropriate time (b)) must be filed and granted to res	limit under 37 CF tore the applicatio	R 1.494 or 1.495 has in to pending status.	not been m	et, a petition to revive	(37 CFR 1.137(a) or
SEND ALL CORRESPONDENCE TO:				1111	gimen >
BROWDY AND NEIMARK,	P.L.L.C		_	SIMATURE (1
624 NINTH STREET, N.W.,	SUITE 300			Sheridan Neimarl	
WASHINGTON, D.C. 20001	JULIE 300			NAME	j
TEL: (202) 628-5197				20,520	
FAX: (202) 737-3528				REGISTRATION NU	MBER
Date of this submission: January 16.	2001				ĺ
Form PTO-1390 (as slightly revised by Browdy a	nd Neirr ark)			Page 2	of 2

· . .

15

25

JC07 Rec'd PCT/PT0 1 6 JAN 2001

SPECIFICATION

HAIR GROWTH TONIC

5 TECHNICAL FIELD

The present invention relates to a hair growth tonic. More specifically, it relates to a growth tonic for hair, which contains the filtrate of lactic acid bacterial cultures as its active ingredient.

BACKGROUND ART

A hair consists of a hair shaft that sticks out from the skin surface and a hair root that is inside the skin. The hair root is encapsulated in a hair follicle. The hair root further contains the hair bulb and a hair papilla. The hair papilla has capillaries and nerves, and regulates the formation and growth of the hair through uptake of nutrients from food and oxygen. At a location close to the hair papilla, there are hair matrix cells that generate the hair. In other words, the hair matrix cells take in nutrients and oxygen from the capillaries that enter the hair papilla and hair is formed by repeated division of the cells.

Each hair has an independent lifecycle. Hairs, as a whole, repeat the cycle of growth, falling off, and generation of new hair. In fact, the hair follicle has a hair cycle of growth

20

25

phase (anagen), regressive phase (catagen) and a resting phase (telogen). Hair is produced during the growth phase only.

During this period, the hair papilla is large, the hair matrix cells work actively to extend the hair, and the hair bulb extends

up to the subcutaneous tissue. Once the growth stops, the hair follicle passes through a regressive phase. The first symptom of the regressive phase is the stoppage of melanin production by the hair bulb. After then, most of the other cells of the hair follicle are consumed by the surrounding micropahges to shrink. The hair root shrinks up to a position below the arrector pili muscle and the cells enter to the resting phase. Generally, the growth phase of a hair is 5-6 years, the regressive phase thereof is 2-3 weeks and the resting phase thereof is 2-3 months.

When there is some abnormality during the hair cycle, it falls off and baldness starts. The causes of baldness are not fully understood. The lowering of hair follicle function under the influence of the male hormone, the lowering of the metabolic functions of the hair follicle and bulb, the lowering of the physiological functions of the scalp, some localized problem in blood flow due to tension on the scalp, malnutrition, stress, side effects of drugs, heredity, etc could be the reason. Various types of hair growth tonics have been used for preventing and treating baldness. Such hair growth tonics are mostly mixtures of various chemicals that have some effect of

20

25

counteracting at least some of the causes listed above. The main component of most of these tonics is a chemical that either has an activating effect on the hair matrix cells or a blood circulation enhancing effect. Most of these tonics are designed to give a hair growth promoting effect (hair nourishment and hair regeneration) by supplying nutrients through the activation of the hair follicles that show diminished hair growth and through enhanced blood flow.

Hair and baldness have been discussed, for instance, in

Shin Keshohin Gaku (New Cosmetology) compiled by Takeo Mitsui
and published by Nanzando (1994), which may be referred.

Patent applications on various hair tonics and hair growth tonics have been applied for. Some examples are disclosed in Japanese Patent Laid-open Publication No. Sho. 63-303915 (A hair tonic containing skimmia extract), Japanese Patent Publication No. Hei. 4-5002 (A cosmetic hair tonic containing lipase), Japanese Patent Laid-open Publication No. Hei. 1-254614 (A hair tonic containing fermented herbal stimulant and water-soluble chitosan).

As mentioned above, various types of hair tonics and hair growth tonics have been developed. However very few of them are truly effective in suppressing hair loss or promoting hair nourishment and hair growth. Under this situation, it would be very significant to discover a hair growth tonic that is truly effective, because it would be of immense benefit for people

15

20

suffering from baldness.

After extensive research undertaken to overcome the above-mentioned problems, the present inventors found that the filtrate of cultures of some microorganisms, lactic acid bacteria in particular, is effective in the treatment of baldness, and completes the present invention.

Thus, an object of the present invention is to provide a hair growth tonic that can effectively promote hair growth, hair nourishment and hair regeneration (hereinafter referred to simply as "hair growth").

DISCLOSURE OF THE INVENTION

A hair growth tonic according to the present invention is characterized by containing filtrate of lactic acid bacterial cultures, as its active ingredient.

Moreover, a hair growth tonic according to another aspect of the present invention is characterized in that the above-mentioned lactic acid bacterium is a bacterium belonging to Streptococcus or Lactobacillus.

In addition, a hair growth tonic according to another aspect of the present invention is characterized in that the above-mentioned lactic acid bacterium of Streptococcus is Streptococcus lactis.

A hair growth tonic according to still another aspect of 25 the present invention is characterized in that the

25

above-mentioned lactic acid bacterium of Lactobacillus is Lactobacillus bulgaricus.

Furthermore, a hair growth tonic according to another aspect of the present invention is characterized by containing 5 other known hair growth promoting component in addition to the filtrate of the above-mentioned lactic acid bacterial cultures.

Still further, a hair growth tonic according to another aspect of the present invention is characterized in that the above-mentioned known other growth promoting component is 10 laurel extract and/or chlorophyll.

Because of the above-described composition, the filtrate of the lactic acid bacterial cultures have hair growth promoting as well as hair loss preventing effect. It is assumed that the components contained in the filtrate of the lactic acid 15 bacterial cultures have the effect of promoting blood circulation to the peripheral capillaries, and also that the components enhance the division and multiplication of the hair matrix cells and act as hair root activators by improving the lowered functions of the hair matrix cells. Particularly when the lactic acid bacterium belonging to Streptococcus or Lactobacillus is used, various components produced by the lactic acid bacterium, which are present in the filtrate of the lactic acid bacterial culture and are supplied to the hair papilla, act synergistically and have the effect of promoting the growth of the hair matrix cells.

20

25

In the present invention, "filtrate of culture" means the liquid fraction of the lactic acid bacterial culture, obtained by crushing the bacterial cells present in the culture medium (bacterial suspension) to make them into colloidal or dissolved form, and the removing the cellular residue. This filtrate can be separated by solid-liquid separation means like filtration, centrifuging, etc. In one embodiment of the present invention, the lactic acid bacteria used are those belonging to Streptococcus or Lactobacillus. However, in the hair growth tonic of the present invention, it is not limited to use the filtrate of the culture of the specified lactic acid bacteria. The hair growth tonic of the present invention can contain filtrates from cultures of any other lactic acid bacteria having a similar effect.

The hair growth tonic of the present invention can contain other known hair growth promoting components. Examples of such hair growth promoting components are activators of living cells such as laurel extract, and chlorophyll; blood circulation promoters and localized stimulants that promote blood flow to peripheral capillaries; nutrients (such as Vitamins and amino acids) for supplying nutrition to the area surrounding hair matrix cells; female hormone formulations that have antagonistic effect against male hormone; hair root activators for improving the lowered function of hair matrix cells; moisturizers for preventing scalp drying, etc.

20

25

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the comparison of hair growth before the start of the test and the hair growth 4 or 5 months after treatment with the filtrate of cultures of Streptococcus lactis culture from Example 1 (Formulation 2), applied to the scalp of three males (Top: Male A, Middle: Male B and Bottom: Male C) having alopecia.

BEST MODE FOR CARRYING OUT THE INVENTION

The hair growth tonic according to the present invention will be described in greater detail, referring to the Tables and the accompanying drawings.

"Lactic acid bacteria" is a general name for a group of 15 bacteria that obtain their energy by fermenting carbohydrates and produce large quantities of lactic acid. Lactic acid bacteria can be classified into cocci and bacilli. Streptococcus, Leuconostoc, Pediococcus, etc. belong to the group of cocci and Lactobacillus, Vifidobacterium, etc. belong to the group of bacilli. The lactic acid bacteria in the present invention include any types of lactic acid bacteria belonging to the above-mentioned groups. Unnatural lactic acid bacteria such as recombinant lactic acid bacteria, variants of lactic acid bacteria obtained by artificially induced mutations, etc are also included. The preferred lactic acid bacteria are those

20

25

which are not pathogens of humans and other animals. commercially available lactic acid bacteria used manufacturing foods such as fermented milk products, fermented meat products, fermented food, fermented soy bean milk, pickles, 5 etc. can be more preferably used. Such lactic acid bacteria are available from, for example, Chr. Hansen's Corp.

Examples of lactic acid bacteria that can be used in the present invention includes Streptococcus species such as Streptococcus thermophilus, Streptococcus lactis, Streptococcus lactis subap. Diacetilactis; Pediococcus species such as Pediococcus cerevisiae, Pediococcus acidilactici, Pediococcus penntosaceus, Pediococcus halophilus, and Pediococcus urinae-equi; Leuconostoc species such as Leuconostoc cremoris and Leuconostoc oenos; 15 Lactobacillus species such as Lactobacillus delbrueckii, Lactobacillus Lactobacillus leuchmannii, lactis. Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus fermenntum, Lactobacillus brevis, Lactobacillus viridescens; Bifidobacterium species such as longum, Bifidobacterium bifidum, Bifidobacterium Bifidobacterium breve, and Bifidobacterium infantis.

Among these lactic acid bacteria, those belonging to the genus Streptococcus are gram-positive, non-sporulating and obligate to facultative anaerobic cocci of diameter 1 µm or less. Normally, they are diplococci or streptococci. They are

25

negative for catalase and oxidase and produce dextrorotatory lactic acid in the homofermentation mode. Those belonging to the genus Lactobacillus are gram-positive, negative for catalase, and are obligate anaerobes to anaerobes. Normally they are non-motile, do not produce spores, are bacilli, and aggregate into chains also. Both homofermentation and heterofermentation types are known to exist.

In one embodiment of the present invention, the filtrate of cultures of two of the lactic acid bacteria listed above,

Streptococcus lactis and Lactobacillus bulgaricus, are used.

Streptococcus lactis belongs to cocci and Lactobacillus bulgaricus is a bacillum. Both are homofermentation type lactic acid bacteria. Streptococcus lactis is used as a starter in the production of dairy products such as fermented milk,

these, and butter. Lactobacillus bulgaricus is used as a starter for cheese and also widely used in the production of lactic acid drinks, yogurt, and the like.

The filtrate of the lactic acid bacterial culture used in the present invention can be obtained by culturing the above-mentioned lactic acid bacteria, removing the solid components left after crushing the bacterial cells of the lactic acid bacteria in the culture medium obtained, i.e., the residue of the bacterial cells left after making the cell wall portion into a colloid or dissolving it.

The lactic acid bacterial culture can be produced under

15

20

25

any conditions, as long as they permit satisfactory multiplication of the lactic acid bacteria. The composition of culture medium, culturing temperature, culturing pH, culturing time, etc. may be varied, depending on the type of the lactic acid bacteria used. The culturing conditions and culturing method, for instance, can be selected from those given in Bergey's Manual of Determinative Bacteriology (8th Edition, 1974) and those given in the user's manuals provided by the manufacturers of commercially available lactic acid bacteria.

The medium can be prepared, for example, by combining one or more carbon sources and nitrogen sources such as whey glucose, and peptone. The culturing temperature can be varied, depending on the type of bacterium used. The normally used culturing temperature (approx. 20-45°C) is suitable. The culturing can be done at an even higher temperature in the case of heat-resistant lactic acid bacteria. The bacteria grow quite well in the pH range 2-4. However, the culturing pH of the initial medium may be neutral or weakly alkaline.

The culturing may be done for a period of a few hours to 72 hours, preferably for about 15-50 hours. The amount of lactic acid bacterium culture to be added per liter of the medium is 10-100 ml.

A set of the culturing conditions is given below, as an example. But this in no way limits the scope of the invention.

When the lactic acid bacteria belonging to the genus

20

Streptococcus are used, the culturing can be done in the MRS medium (available from Difco, Co.) at 30-37°C and pH 6.8, for 24-48 hours. In the case of the lactic acid bacteria belonging to the genus Leuconostoc also, culturing can be done in the MRS medium at 30-37°C, and pH 6.8, for 24-48 hours. For the lactic acid bacteria belonging to the genus Pediococcus also, culturing can be done in the MRS medium at 30-37°C and pH 6.8, for 24-48 hours.

In the case of the lactic acid bacteria belonging to the \$10\$ genus Lactobacillus also, culturing can be done in the MRS medium at 30-37 $^{\circ}\text{C}$ and pH 6.8, for 24-48 hours.

For the lactic acid bacteria belonging to the genus Bifidobacterium, the culturing may be done in BL or EG medium under anaerobic conditions at $30-37\,^{\circ}\text{C}$ and pH 7-8, for 24-48 hours.

In a specific example of the present invention, a medium containing whey and glucose (10% and 2%, respectively, for example) is inoculated with a lactic acid bacterium, and stationary culturing is done at $35-37^{\circ}$ C for 48 hours.

After culturing the lactic acid bacteria, the bacterial cells are crushed, the culture suspension is filtered or centrifuged to remove the residue of bacterial cells, and the filtrate of cultures is recovered.

 $\label{eq:compositions} \mbox{The media described above are given} 25 below.$

MRS medium (for 1 liter of medium)

	Peptone (Oxoid)	10 g
	Meat extract	10 g
	Yeast extract	5 g
5	K ₂ HPO ₄	2 g
	Diammonium hydrogen citrate	2 g
	Glucose	20 g
	Tween 80	1 g
	Sodium acetate	5 g
10	${\tt MgSO_4\cdot 7H_2O}$	0.58 g
	MnSO ₄ ·4H ₂ O	0.28 g

(The volume was made up to 1 liter with purified water, pH 6.2-6.6, sterilized for 15 minutes at 121°C)

BL (Agar) medium

15	Beef extract (Oxoid)	3 g
	Proteose peptone No. 3 (Difco)	10 g
	Trypticase (BBL)	5 g
	Phytone (BBL)	3 g
	Yeast extract (Difco)	5 g
20	Liver extract	150 ml
	Glucose	10 g
	Soluble starch	0.5 g
	Solution A	10 ml
	Solution B	5 ml
25	Tween 80	1 q

15

20

25

Bactoagar (Difco) 15 g

L-Cysteine hydrochloride (5% solution) 10 ml

Horse blood 50 ml

Purified water 765 ml

5 pH 7.2

Solution A: 25 g of K_2HPO_4 and 25 g of K_2HPO_4 are dissolved in 250 ml of distilled water.

Solution B: 10 g of MgSO $_4$ ·7H $_2$ O, 0.5 g of FeSO $_4$ ·7H $_2$ O, 0.5 g of NaCl, and 0.337 g of MnSO $_4$ are dissolved in 250 ml of purified water.

Liver extract: 10 g of liver powder (Kyokuto) is extracted for about one hour in 170 ml of purified water placed in a $50-60\,^{\circ}\text{C}$ warm water bath. It is heated for several minutes at $100\,^{\circ}\text{C}$ and filtered through filter paper after adjusting the pH thereof to 7.2.

Preparation of medium: The components other than the L-cysteine hydrochloride and horse blood are heated to dissolve them. Then, after adjusting the pH, the solution is sterilized for 20 minutes at 115° C. The solution is then cooled to 50° C, the cysteine hydrochloride and horse blood are added to prepare flats.

EG (EUGON) medium

Bactotryptose (Difco) 1.5%

Bactosoeton (Difco) 0.5%

Bactodextrose (Difco) 0.55%

20

25

L-Cysteine	(Difco)	0.07%
NaCl		0.4%
Na ₂ SO ₃		0.02%
Durified wa	ter to make	100%

The hair growth tonic of the present invention contains the filtrate of a lactic acid bacterial culture thus obtained as its active component. The amount of the filtrate of cultures in the composition is as much as would give a suitable effect on hair growth, and is not particularly limited. It can, for 10 example, be 0.1% or more, preferably 0.1-20% (% by volume in all cases). The filtrate of the lactic acid bacterial culture of the present invention can be concentrated to a suitable level, such as 2-10 times, preferably 3-5 times, by employing an ordinary method of concentration, before adding to the hair growth tonic as the active ingredient.

Lactic acid bacteria are known to synthesize vitamins of the B group inside human guts, activate leukocytes, enhance the bacterial infection preventing activity by strengthening the immune system, and produce antibacterial substances that exclude harmful bacteria. They are also known to adsorb carcinogens and enable their excretion through human stools, and to have a blood cholesterol lowering effect. Through the present invention, it has now become clear that the filtrate of cultures thereof have hair growth promoting and hair loss prevention effect. Some components contained in the filtrates

15

20

25

of lactic acid bacterial cultures have the effect of promoting blood flow to the terminal capillaries, promoting of the division and multiplication of hair matrix cells, activation of hair roots which improves the lowered functions $\,\,\,\,\,\,\,\,\,\,\,\,\,$ of the hair matrix cells. Which components are effective is not very clear. However, it is assumed that various components produced by lactic acid bacteria, which are present in the filtrate of lactic acid bacterial cultures, act synergistically when supplied to the hair papilla and exert a hair growth promoting effect on the hair matrix cells.

In the hair growth tonic of the present invention, the above-described culture filtrate can be used singly. However, for the sake of ease in use, it is preferable to use it along with carriers such as excipients and diluents permitted in drugs (including quasi drugs, used with this meaning hereinafter) and cosmetics. Examples of such carriers include purified water, ordinary water, physiological saline, ethanol, etc., all of which are normally used in hair growth tonics.

The hair growth tonic of the present invention can contain other known hair growth promoting components. Examples of such components include activators of living cells (for example laurel extract, chlorophyll, etc.); blood flow promoters (such as alder fly extract, cephalanthin, Vitamin E and its derivatives, y-orizanol, etc) and local stimulants (such as capsicum tincture, ginger tincture, cantharis tincture, benzyl

20

25

ester of nicotinic acid, etc) that promote blood flow to the peripheral capillaries; nutrient preparation that supply nutrients (for example, Vitamins A, B₁, B₂, B₆, E and their derivatives, pantothenic acid and its derivatives, vitamins such as biotin, amino acids such as cystine, cysteine, methionine, leucine, tryptophan, amino acid extracts) to the area surrounding the hair matrix cells; female hormones (for example, estradiol, ethynylestradiol, etc) which have antagonistic action against the male hormone; hair root activators (such as pantothenic acid and its derivatives, placenta extract, allantoin, Kanko-so No. 301, etc) for improving the lowered function of the hair matrix cells; moisturizers (such as glycerol and pyrrolidone carboxylic acids) to prevent drying of the scalp, etc.

The hair growth tonic of the present invention can also contain drugs for preventing dandruff and itchiness. Examples of such drugs include keratin exfoliant-resolvents such as salicylic acid, sulfur, resorcinol, and selenium sulfide; anti-seborrhea agents such as pyridoxine and its derivatives; disinfectants such as pyrethion zinc, trichlorocarbanilide/acetic acid tocophenol, benzalkonium chloride, benzethonium chloride, chlorohexidine, and hinoki (Japanese cypress) thiol; antiinflammatory agents such as glycyrrhetic acid and its derivatives, hydrocortisone acetate, and prednisolone; antipruritic agent such as diphenhydramine

20

25

hydrochloride, maleic acid chlorophenylamine, camphor, and dlor 1-menthol. In addition to these, it can contain suitable amounts of components described in Keshohin Betsu Kyokakijun (Permissible Standards for Cosmetics) (Yakuji Nopposha) such as perfumes, fresheners, emulsifiers, solubilizing agents, pH regulators, and coloring agents.

The hair growth tonic of the present invention can be used as a drug as well as a cosmetic. Its effects as a drug are the improvement and prevention of circular alopecia areata, premature alopecia, and male pattern alopecia. It is also effective in promoting hair revival, hair regeneration, hair growth, and hair nourishment, and in preventing falling of hair. Because of this, the hair growth tonic of the present invention can be used effectively as a cosmetic. The lactic acid bacteria 15 used in the present invention are used in the preparation of food or are naturally present in food. Thus, the bacterial culture medium has a very low toxicity.

The hair growth tonic may be in the form of a liquid formulation, emulsion, cream, lotion, gel, liquid, foam, spray, etc. It can also be compounded with shampoos, rinses, and treatments. For example, oil and fats (such as olive oil, and triglyceride), hydrocarbons (such as liquid paraffin, vaseline, and yellow beeswax), higher fatty acids, higher fatty acid esters, higher alcohols, surfactants, tackifiers, chelating agents, and the like may be used to prepare a cream. To prepare

15

20

25

a gel, water soluble polymers (such as carboxyvinyl polymer, and methyl cellulose), setting agents (such as polyvinylpyrrolidone), alkalies, surfactants, chelating agents, and the like may be used. If it is in the form of a spray or foam, atomizing agents (such as dimetyl ether, and liquefied petroleum gas) may be used. Gums (such as gum tragacanth, and gum karaya), polymers (such as polyvinylpyrrolidone/vinyl acetate copolymer), and the like may be used in the case of lotions.

The hair growth tonic of the present invention may be applied (for example, by spraying 1 ml) on the scalp at least once a day, preferably twice or more often, and the scalp may be stimulated by tapping or massaging to achieve a significant hair growth promoting effect.

The hair growth tonic of the present invention will now be explained in greater detail referring to some examples. However, the scope of the invention is not limited by these examples.

[Example 1] Preparation of hair growth tonic containing filtrate of a Streptococcus lactis culture

A medium prepared by adding 10% of whey and 2% of glucose to 1 liter of sterilized water was inoculated with 50 ml of Streptococcus lactis. It was then subjected to stationary culture for 48 hours at 35°C. After culturing, the cell walls were crushed, made into a colloid and dissolved. This bacterial

25

suspension was centrifuged to remove the bacterial cell residues. The culture filtrate thus obtained was used in the preparation of the following examples of the hair growth tonic (the quantities are expressed in % by volume).

5 Formulation 1

	Filtrate of Streptococcus lactis culture	1.5%
	Pure water to make up	100%
	Formulation 2	
	Filtrate of Streptococcus lactis culture	1.5%
)	Laurel extract	0.5%
	Ethanol	15%
	Pure water to make up	100%
	Formulation 3	
	Filtrate of Streptococcus lactis culture	1.5%
5	Capsicum tincture	0.1%
	dl-Menthol	0.1%
	Water-soluble placenta extract	0.1%
	Laurel extract	0.5%
	Ethanol	15%

[Example 2] Preparation of hair growth tonic containing filtrate of Lactobacillus bulgarious culture

Pure water to make up

100%

A medium prepared by adding 10% of whey and 2% of glucose to 1 liter of sterilized water was inoculated with 50 ml of Lactobacillus bulgaricus. It was then subjected to stationary

culture for 48 hours at 35°C. After culturing, the cell walls were crushed, made into a colloid and dissolved. This bacterial suspension was centrifuged to remove the bacterial cell residues. The culture filtrate thus obtained was used in the preparation of the following examples of the hair growth tonic

(the quantities are expressed in % by volume).

Formulation 4

	Filtrate of Lactobacillus bulgaricus culture	1.5%
	Purified water to make up	100%
10	Formulation 5	
	Filtrate of Lactobacillus bulgaricus culture	1.5%
	Laurel extract	0.5%
	Ethanol	15%
	Purified water to make up	100%
15	Formulation 6	
	Filtrate of Lactobacillus bulgaricus culture	1.5%
	Capsicum tincture	0.1%
	dl-Menthol	0.1%
	Water-soluble placenta extract	0.1%
20	Laurel extract	0.5%
	Ethanol	15%
	Purified water to make	100%

[Example 3] Hair growth test and results

A suitable amount of the hair growth tonic of Example 1 25 (Formulation 2) was applied twice a day, morning and evening,

on the scalp of three alopecic males. The effect of 4 or 5 months of treatment was evaluated visually. Significant effect on hair growth occurred in all the cases (refer to Fig. 1). Similar positive effect on hair growth was confirmed with the hair growth tonic of Example 2 (Formulation 5) when applied on three alopecic men, for 2-3 months. The results are shown in Table 1 (for Formulation 2) and Table 2 (for Formulation 5).

[Table 1]

Test subject	Sex & Age	Duration of use	Effect
А	Male, in his	40's 4 months	++
В	Male, in his	40's 5 months	+++
С	Male, in his	40's 5 months	++

[Table 2]

15	Test subject	Sex & Age	Duration of use	Effect
	D	Male, in his 50'	s 3 months	++
	E	Male, in his 50'	s 3 months	++
	F	Male, in his 60's	s 2 months	+

20 Meaning of symbols

- : Worsened

0 : No visible effect

+ : No visible effect, but positive effect could be confirmed by microscopic observation

25 ++ : Effect was visible

+++ : Very significant effect could be seen

The above examples show that the hair growth tonic of the present invention is effectively used in prevention of hair loss and its treatment.

5 [Example 4] Preparation of hair growth tonic and hair growth

Formulation 7

Filtrate of Streptococcus lactis 2%
Purified water to make us 100%

15 (1) Male I (50 years old)

The subject was bald on the back of his head. This baldness was so extensive that the even the hair whirl at the top of the head could not be seen. Starting from October 1999 about 5 cc of the hair growth tonic prepared according to the Formulation 7 was sprayed daily on the back of his head, for about 3 months. His hair growth recovered almost to the level of the surrounding area.

(2) Male G (65 years old)

His head was as bald as an egg. When about 5 cc of the $\,$ above-mentioned hair growth tonic was applied daily, for about

2 years starting from January 1998, hair growth recovered to the level of a close cropped head of hair.

(3) Male K (60 years old)

He was not bald. When about 3 cc of the tonic was applied daily for 10 days starting from January 10, 2000, the falling of hair and dandruff disappeared.

INDUSTRIAL APPLICABILITY

As discussed above, the hair growth tonic according to 10 the present invention leffectively promotes hair growth. It is useful as a drug and cosmetic that can prevent hair loss.

15

CLAIMS

- A hair growth tonic containing a filtrate of lactic acid bacterial culture as an active ingredient.
- The hair growth tonic according to claim 1,
 characterized in that the lactic acid bacterium is a bacterium belonging to Streptococcus or Lactobacillus.
 - 3. The hair growth tonic according to claim 2, characterized in that the lactic acid bacterium of Streptococcus is Streptococcus lactis.
 - 4. The hair growth tonic according to claim 2, characterized in that the lactic acid bacterium of Lactobacillus is Lactobacillus bulgaricus.
 - 5. The hair growth tonic according to claim 2, characterized by further comprising other components known to promote hair growth.
 - 6. The hair growth tonic according to claim 5, characterized in that the other components known to promote hair growth are laurel extract and/or chlorophyll.

ABSTRACT

A hair growth tonic contains, as an active ingredient,
a filtrate of lactic acid bacterial culture such as
Streptococcus lactis, and Lactobacillus bulgaricus. The use
of this type of hair growth tonic promotes hair regeneration,
hair growth and hair nourishment.

1/1

Fig. 1

Before treatment

Male A (top of head)



Male B (back of head)




Male C (back of head)



After treatment

After 4 months



After 5 months



After 5 months



(include dates of amendments under PCT Art. 19 and 34 if PCT)

The state of the s

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only on name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a natent is sought on the invention entitled.

matter which is claim	med and for which a patent is sought on the invention entitled	
_ HAIR GROW	TH STIMULANTS	
the specification of w	which (check one)	
[]	is attached hereto;	
[]	was filed in the United States under 35 U.S.C. §111 on	, as
	U.S. Appin. No*; or	
[x]	was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the	U.S. national stage of an international
	(PCT) application, PCT/JP00/03017 filed May 11, 2000 , en	try requested on
	national stage application received U.S. Appln. No*; §3	371/§102(e) date
	(* if known)	
		allaakia)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.P.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 and 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

11-134132	Japan	_14/05/1999	Ñ	0
(Number)	(Country)	(Day Month Year Filed)	YES	NO
			0	0
(Number)	(Country)	(Day Month Year Filed)	YES	NO

I hereby claim the benefit under 35 U.S.C. \$120 of any prior U.S. non-provisional application(s) or prior PCT application(s) designating the U.S. listed below, or under \$\frac{8}{1}\)19(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. \$11.2, 1 acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. \$1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practioners associated with <u>Customer Number 001444</u>

Direct all correspondence to the address associated with <u>Customer Number 001444</u>; i.e.,

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from $\underline{KANESAKA} \& SAKAI$ as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

POST OFFICE ADDRESS

i.

· · · · · · · · · · · · · · · · · · ·			
age 2 of 2 Pages			Atty. Docket:
I.S. Application filed	. Serial No.		
J.S. Application filed	, Serial No.		
hereby further declare that all statements made her nd belief are believed to be true; and that these stat o made are punishable by fine or imprisonment, eopardize the validity of the application or any pat	ements were made with the knowledge or both, under 18 U.S.C. §1001 and	e that willful false sta	tements and the like
FULL NAME OF FIRST INVENTOR	INVENTOR'S SIGNATURE		DATE
_Isao HORIUCHI	- las Thornichic	<i></i>	24/12/2000
RESIDENT 1014-banchi, Ichinomiya	Tehinomiya-cho	CITIZENSHIP	-01
Higashi-Yatsushiro-qun, Yaman	ashi-ken 405-0056 JAPA	N JAPAN	ESE JPX
POST OFFICE ADDRESS As above	doni non, 105 0050 oni.	511 - 51111111	
	INVENTOR'S SIGNATURE		DATE
FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
DESIDENT		CITIZENSHIP	

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.